Why it matters for patients

The Immuno-oncology Portal (IOP) was created to provide up-to-date and accessible information about cancer immunotherapies, which are treatments that stimulate the body’s own immune system to seek out and destroy cancer. The field of cancer immunology is growing and changing rapidly as is the number of possible treatments. Some cancers like advanced melanoma that previously was considered untreatable can in some instances now be treated by immunotherapies. As a contrast to the promising outlook these new therapies bring to cancer patients however, we found it very difficult to find easily accessible and understandable information about them. We therefore went on to establish the IOP in 2015 to inform patients, healthcare providers, policymakers, and stakeholders about the promises of immunotherapies guided by two principles: Patient-centeredness and scientific accuracy. The portal aims to empower patients and caregivers by offering its content in a simple and understandable way. All the information on the portal is scientifically accurate and is continuously updated to reflect the newest advances in immuno-oncology. We recommend you read about how to use each tool before you interact with it.

Interact with one or both eLearning modules for an introduction to immuno-oncology or browse the accessibility database to see which cancer immunotherapies are authorized and reimbursed across Europe

How to make the most of this tool

The IOP is divided into two main sections: The first provides an introduction to cancer immunology while the second provides a comprehensive list of the availability and reimbursement of immunotherapies across Europe.

If you are new to immuno-Oncology, we suggest you first browse the eLearning modules to familiarise yourself with how the treatment functions. Module I provides an overview of the five most important types of cancer immunotherapies while Module II explains in greater detail how immunotherapies affect the immune system and how these treatments and side effects are different from alternatives such as surgery, chemo- and radio-therapy.

If you want to know whether a specific immunotherapy is available and reimbursed where you live or in another European country, we invite you to browse our accessibility database. The database lists annually updated information about all immunotherapies that are authorized for use in the EU and EFTA. The information is sorted by country and you can quickly learn which treatments are available and reimbursed across Europe. The database also lists which types of cancer each treatment is meant for.

IOP Database

Active substance Country Indication Availability Reimbursement Source
Active substance Country Indication Availability Reimbursement Source
Atezolizumab Austria Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Austria Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Austria Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Austria Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Austria Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Nivolumab United Kingdom Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab United Kingdom Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab United Kingdom Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab United Kingdom Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab United Kingdom Breast Neoplasms Available Reimbursed Source
Ramucirumab United Kingdom Stomach Neoplasms Available Not reimbursed Source
Rituximab United Kingdom Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b United Kingdom Polycythemia Vera Available Not reimbursed Source
Talimogene laherparepvec United Kingdom Melanoma Available Reimbursed Source
Tisagenlecleucel United Kingdom Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Trastuzumab United Kingdom Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine United Kingdom Breast Neoplasms Available Reimbursed Source
Atezolizumab United Kingdom Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab United Kingdom Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel United Kingdom Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Bevacizumab United Kingdom Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab United Kingdom Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin United Kingdom Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab United Kingdom Carcinoma, Squamous Cell Available Reimbursed Source
Cetuximab United Kingdom Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab United Kingdom Multiple Myeloma Available Reimbursed Source
Denosumab United Kingdom Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Unavailable Not reimbursed Source
Dinutuximab beta United Kingdom Neuroblastoma Available Reimbursed Source
Durvalumab United Kingdom Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab United Kingdom Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin United Kingdom Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan United Kingdom Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin United Kingdom Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b United Kingdom Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab United Kingdom Melanoma Available Reimbursed Source
Mogamulizumab United Kingdom Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab United Kingdom Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Ropeginterferon alfa-2b Sweden Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Sweden Melanoma Available Not reimbursed Source
Tisagenlecleucel Sweden Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Sweden Breast Neoplasms Stomach Neoplasms Available Not reimbursed Source
Trastuzumab emtansine Sweden Breast Neoplasms Available Not reimbursed Source
Elotuzumab Sweden Multiple Myeloma Available Not reimbursed Source
Gemtuzumab ozogamicin Sweden Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Sweden Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Sweden Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Interferon alfa-2b Sweden Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Reimbursed Source
Ipilimumab Sweden Melanoma Available Not reimbursed Source
Mogamulizumab Sweden Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Sweden Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Sweden Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Not reimbursed Source
Obinutuzumab Sweden Leukemia, Lymphocytic, Chronic, B-Cell Available Not reimbursed Source
Panitumumab Sweden Colorectal Neoplasms Available Not reimbursed Source
Pembrolizumab Sweden Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Not reimbursed Source
Pertuzumab Sweden Breast Neoplasms Available Not reimbursed Source
Ramucirumab Sweden Stomach Neoplasms Available Not reimbursed Source
Rituximab Sweden Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Pertuzumab Spain Breast Neoplasms Available Reimbursed Source
Ramucirumab Spain Stomach Neoplasms Available Reimbursed Source
Rituximab Spain Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Spain Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Spain Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Spain Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Trastuzumab Spain Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Spain Breast Neoplasms Available Reimbursed Source
Atezolizumab Sweden Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Not reimbursed Source
Avelumab Sweden Carcinoma, Merkel Cell Available Not reimbursed Source
Axicabtagene ciloleucel Sweden Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Bevacizumab Sweden Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Not reimbursed Source
Blinatumomab Sweden Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Brentuximab vedotin Sweden Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Sweden Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Sweden Colorectal Neoplasms Head and Neck Neoplasms Available Not reimbursed Source
Daratumumab Sweden Multiple Myeloma Available Not reimbursed Source
Denosumab Sweden Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Sweden Neuroblastoma Available Not reimbursed Source
Durvalumab Sweden Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Blinatumomab Spain Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Brentuximab vedotin Spain Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Spain Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Spain Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Spain Multiple Myeloma Available Reimbursed Source
Denosumab Spain Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Spain Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Spain Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Spain Multiple Myeloma Available Not reimbursed Source
Gemtuzumab ozogamicin Spain Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Spain Lymphoma, Follicular Available Reimbursed Source
Inotuzumab ozogamicin Spain Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Spain Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Spain Melanoma Available Reimbursed Source
Mogamulizumab Spain Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Spain Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Spain Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Spain Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Spain Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Spain Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Interferon alfa-2b Slovenia Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Not reimbursed Source
Ipilimumab Slovenia Melanoma Available Reimbursed Source
Mogamulizumab Slovenia Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Slovenia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Slovenia Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Slovenia Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Slovenia Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Slovenia Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Slovenia Breast Neoplasms Available Reimbursed Source
Ramucirumab Slovenia Stomach Neoplasms Available Reimbursed Source
Rituximab Slovenia Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Slovenia Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Slovenia Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Slovenia Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Slovenia Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Slovenia Breast Neoplasms Available Reimbursed Source
Atezolizumab Spain Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Spain Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Spain Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Bevacizumab Spain Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Talimogene laherparepvec Slovakia Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Slovakia Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Slovakia Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Slovakia Breast Neoplasms Available Reimbursed Source
Atezolizumab Slovenia Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Not reimbursed Source
Avelumab Slovenia Carcinoma, Merkel Cell Available Not reimbursed Source
Axicabtagene ciloleucel Slovenia Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Slovenia Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Slovenia Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Slovenia Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Slovenia Carcinoma, Squamous Cell Unavailable Reimbursed Source
Cetuximab Slovenia Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Slovenia Multiple Myeloma Available Reimbursed Source
Denosumab Slovenia Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Slovenia Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Slovenia Carcinoma, Non-Small-Cell Lung Unavailable Reimbursed Source
Elotuzumab Slovenia Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Slovenia Leukemia, Myeloid, Acute Unavailable Not reimbursed Source
Ibritumomab tiuxetan Slovenia Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Slovenia Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Daratumumab Slovakia Multiple Myeloma Available Reimbursed Source
Denosumab Slovakia Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Slovakia Neuroblastoma Available Not reimbursed Source
Durvalumab Slovakia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Elotuzumab Slovakia Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Slovakia Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Slovakia Lymphoma, Follicular Unavailable Reimbursed Source
Inotuzumab ozogamicin Slovakia Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Slovakia Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Reimbursed Source
Ipilimumab Slovakia Melanoma Available Not reimbursed Source
Mogamulizumab Slovakia Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Slovakia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Slovakia Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Not reimbursed Source
Obinutuzumab Slovakia Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Slovakia Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Slovakia Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Slovakia Breast Neoplasms Available Reimbursed Source
Ramucirumab Slovakia Stomach Neoplasms Available Not reimbursed Source
Rituximab Slovakia Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Slovakia Polycythemia Vera Unavailable Not reimbursed Source
Nivolumab Romania Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Romania Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Romania Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Romania Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Romania Breast Neoplasms Available Reimbursed Source
Ramucirumab Romania Stomach Neoplasms Available Reimbursed Source
Rituximab Romania Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Romania Polycythemia Vera Available Not reimbursed Source
Talimogene laherparepvec Romania Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Romania Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Romania Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Romania Breast Neoplasms Available Reimbursed Source
Atezolizumab Slovakia Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Not reimbursed Source
Avelumab Slovakia Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Slovakia Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Slovakia Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Slovakia Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Slovakia Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Slovakia Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Slovakia Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Atezolizumab Romania Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Not reimbursed Source
Avelumab Romania Carcinoma, Merkel Cell Unavailable Reimbursed Source
Axicabtagene ciloleucel Romania Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Romania Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Romania Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Romania Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Romania Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Romania Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Romania Multiple Myeloma Available Reimbursed Source
Denosumab Romania Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Not reimbursed Source
Dinutuximab beta Romania Neuroblastoma Available Not reimbursed Source
Durvalumab Romania Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Elotuzumab Romania Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Romania Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Romania Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Romania Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Interferon alfa-2b Romania Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Romania Melanoma Available Reimbursed Source
Mogamulizumab Romania Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Romania Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Elotuzumab Portugal Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Portugal Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Portugal Lymphoma, Follicular Unavailable Reimbursed Source
Inotuzumab ozogamicin Portugal Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Interferon alfa-2b Portugal Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Portugal Melanoma Available Reimbursed Source
Mogamulizumab Portugal Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Portugal Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Portugal Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Portugal Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Portugal Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Portugal Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Portugal Breast Neoplasms Available Not reimbursed Source
Ramucirumab Portugal Stomach Neoplasms Available Reimbursed Source
Rituximab Portugal Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Portugal Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Portugal Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Portugal Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Portugal Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Portugal Breast Neoplasms Available Reimbursed Source
Pertuzumab Poland Breast Neoplasms Available Reimbursed Source
Ramucirumab Poland Stomach Neoplasms Available Not reimbursed Source
Rituximab Poland Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Poland Polycythemia Vera Available Not reimbursed Source
Talimogene laherparepvec Poland Melanoma Available Not reimbursed Source
Tisagenlecleucel Poland Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Poland Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Poland Breast Neoplasms Available Not reimbursed Source
Atezolizumab Portugal Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Portugal Carcinoma, Merkel Cell Unavailable Not reimbursed Source
Axicabtagene ciloleucel Portugal Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Portugal Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Not reimbursed Source
Blinatumomab Portugal Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Portugal Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Portugal Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Portugal Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Portugal Multiple Myeloma Available Reimbursed Source
Denosumab Portugal Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Portugal Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Portugal Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Blinatumomab Poland Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Poland Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Poland Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Poland Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Poland Multiple Myeloma Available Reimbursed Source
Denosumab Poland Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Poland Neuroblastoma Available Not reimbursed Source
Durvalumab Poland Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Elotuzumab Poland Multiple Myeloma Available Not reimbursed Source
Gemtuzumab ozogamicin Poland Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Poland Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Poland Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Interferon alfa-2b Poland Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Not reimbursed Source
Ipilimumab Poland Melanoma Available Reimbursed Source
Mogamulizumab Poland Sezary Syndrome, Mycosis Fungoides Available Not reimbursed Source
Necitumumab Poland Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Nivolumab Poland Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Poland Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Poland Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Poland Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Interferon alfa-2b Norway Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Not reimbursed Source
Ipilimumab Norway Melanoma Available Reimbursed Source
Mogamulizumab Norway Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Norway Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Norway Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Norway Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Norway Colorectal Neoplasms Available Not reimbursed Source
Pembrolizumab Norway Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Norway Breast Neoplasms Available Reimbursed Source
Ramucirumab Norway Stomach Neoplasms Available Reimbursed Source
Rituximab Norway Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Not reimbursed Source
Ropeginterferon alfa-2b Norway Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Norway Melanoma Available Not reimbursed Source
Tisagenlecleucel Norway Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Trastuzumab Norway Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Norway Breast Neoplasms Available Reimbursed Source
Atezolizumab Poland Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Poland Carcinoma, Merkel Cell Available Not reimbursed Source
Axicabtagene ciloleucel Poland Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Bevacizumab Poland Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Talimogene laherparepvec Netherlands Melanoma Available Reimbursed Source
Tisagenlecleucel Netherlands Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Netherlands Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Netherlands Breast Neoplasms Available Reimbursed Source
Atezolizumab Norway Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Norway Carcinoma, Merkel Cell Available Not reimbursed Source
Axicabtagene ciloleucel Norway Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Norway Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Not reimbursed Source
Blinatumomab Norway Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Brentuximab vedotin Norway Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Norway Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Norway Colorectal Neoplasms Head and Neck Neoplasms Available Not reimbursed Source
Daratumumab Norway Multiple Myeloma Available Reimbursed Source
Denosumab Norway Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Norway Neuroblastoma Unavailable Reimbursed Source
Durvalumab Norway Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Norway Multiple Myeloma Available Not reimbursed Source
Gemtuzumab ozogamicin Norway Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Norway Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Norway Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Ropeginterferon alfa-2b Netherlands Polycythemia Vera Available Not reimbursed Source
Daratumumab Netherlands Multiple Myeloma Available Reimbursed Source
Denosumab Netherlands Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Netherlands Neuroblastoma Available Not reimbursed Source
Durvalumab Netherlands Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Netherlands Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Netherlands Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Netherlands Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Netherlands Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Netherlands Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Netherlands Melanoma Available Reimbursed Source
Mogamulizumab Netherlands Sezary Syndrome, Mycosis Fungoides Available Not reimbursed Source
Necitumumab Netherlands Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Nivolumab Netherlands Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Netherlands Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Netherlands Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Netherlands Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Netherlands Breast Neoplasms Available Reimbursed Source
Ramucirumab Netherlands Stomach Neoplasms Available Reimbursed Source
Rituximab Netherlands Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Nivolumab Malta Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Malta Leukemia, Lymphocytic, Chronic, B-Cell Unavailable Not reimbursed Source
Panitumumab Malta Colorectal Neoplasms Unavailable Not reimbursed Source
Pembrolizumab Malta Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Unavailable Not reimbursed Source
Pertuzumab Malta Breast Neoplasms Unavailable Not reimbursed Source
Ramucirumab Malta Stomach Neoplasms Unavailable Not reimbursed Source
Rituximab Malta Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Malta Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Malta Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Malta Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Malta Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Malta Breast Neoplasms Unavailable Not reimbursed Source
Atezolizumab Netherlands Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Netherlands Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Netherlands Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Bevacizumab Netherlands Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Netherlands Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Netherlands Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Netherlands Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Netherlands Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Atezolizumab Malta Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Unavailable Not reimbursed Source
Avelumab Malta Carcinoma, Merkel Cell Unavailable Not reimbursed Source
Axicabtagene ciloleucel Malta Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Malta Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Malta Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Brentuximab vedotin Malta Hodgkin Disease Lymphoma, Non-Hodgkin Unavailable Not reimbursed Source
Cemiplimab Malta Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Malta Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Malta Multiple Myeloma Unavailable Not reimbursed Source
Denosumab Malta Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Unavailable Not reimbursed Source
Dinutuximab beta Malta Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Malta Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Elotuzumab Malta Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Malta Leukemia, Myeloid, Acute Unavailable Not reimbursed Source
Ibritumomab tiuxetan Malta Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Malta Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Interferon alfa-2b Malta Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Malta Melanoma Unavailable Not reimbursed Source
Mogamulizumab Malta Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Malta Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Elotuzumab Luxembourg Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Luxembourg Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Luxembourg Lymphoma, Follicular Available Reimbursed Source
Inotuzumab ozogamicin Luxembourg Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Luxembourg Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Luxembourg Melanoma Available Reimbursed Source
Mogamulizumab Luxembourg Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Luxembourg Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Luxembourg Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Luxembourg Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Luxembourg Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Luxembourg Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Luxembourg Breast Neoplasms Available Reimbursed Source
Ramucirumab Luxembourg Stomach Neoplasms Available Reimbursed Source
Rituximab Luxembourg Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Luxembourg Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Luxembourg Melanoma Available Reimbursed Source
Tisagenlecleucel Luxembourg Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Trastuzumab Luxembourg Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Luxembourg Breast Neoplasms Available Reimbursed Source
Pertuzumab Lithuania Breast Neoplasms Available Not reimbursed Source
Ramucirumab Lithuania Stomach Neoplasms Available Not reimbursed Source
Rituximab Lithuania Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Not reimbursed Source
Ropeginterferon alfa-2b Lithuania Polycythemia Vera Available Not reimbursed Source
Talimogene laherparepvec Lithuania Melanoma Available Not reimbursed Source
Tisagenlecleucel Lithuania Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Lithuania Breast Neoplasms Stomach Neoplasms Available Not reimbursed Source
Trastuzumab emtansine Lithuania Breast Neoplasms Available Not reimbursed Source
Atezolizumab Luxembourg Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Luxembourg Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Luxembourg Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Bevacizumab Luxembourg Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Luxembourg Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Luxembourg Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Luxembourg Carcinoma, Squamous Cell Available Reimbursed Source
Cetuximab Luxembourg Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Luxembourg Multiple Myeloma Available Reimbursed Source
Denosumab Luxembourg Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Luxembourg Neuroblastoma Available Reimbursed Source
Durvalumab Luxembourg Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Blinatumomab Lithuania Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Brentuximab vedotin Lithuania Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Lithuania Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Lithuania Colorectal Neoplasms Head and Neck Neoplasms Available Not reimbursed Source
Daratumumab Lithuania Multiple Myeloma Available Not reimbursed Source
Denosumab Lithuania Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Lithuania Neuroblastoma Available Not reimbursed Source
Durvalumab Lithuania Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Elotuzumab Lithuania Multiple Myeloma Available Not reimbursed Source
Gemtuzumab ozogamicin Lithuania Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Lithuania Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Lithuania Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Interferon alfa-2b Lithuania Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Not reimbursed Source
Ipilimumab Lithuania Melanoma Available Not reimbursed Source
Mogamulizumab Lithuania Sezary Syndrome, Mycosis Fungoides Available Not reimbursed Source
Necitumumab Lithuania Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Nivolumab Lithuania Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Lithuania Leukemia, Lymphocytic, Chronic, B-Cell Available Not reimbursed Source
Panitumumab Lithuania Colorectal Neoplasms Available Not reimbursed Source
Pembrolizumab Lithuania Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Interferon alfa-2b Liechtenstein Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Liechtenstein Melanoma Available Reimbursed Source
Mogamulizumab Liechtenstein Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Liechtenstein Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Liechtenstein Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Liechtenstein Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Liechtenstein Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Liechtenstein Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Liechtenstein Breast Neoplasms Available Reimbursed Source
Ramucirumab Liechtenstein Stomach Neoplasms Available Reimbursed Source
Rituximab Liechtenstein Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Liechtenstein Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Liechtenstein Melanoma Available Reimbursed Source
Tisagenlecleucel Liechtenstein Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Liechtenstein Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Liechtenstein Breast Neoplasms Available Reimbursed Source
Atezolizumab Lithuania Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Lithuania Carcinoma, Merkel Cell Available Not reimbursed Source
Axicabtagene ciloleucel Lithuania Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Bevacizumab Lithuania Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Not reimbursed Source
Talimogene laherparepvec Latvia Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Latvia Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Latvia Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Latvia Breast Neoplasms Available Not reimbursed Source
Atezolizumab Liechtenstein Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Liechtenstein Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Liechtenstein Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Bevacizumab Liechtenstein Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Liechtenstein Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Liechtenstein Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Liechtenstein Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Liechtenstein Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Liechtenstein Multiple Myeloma Available Reimbursed Source
Denosumab Liechtenstein Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Liechtenstein Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Liechtenstein Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Liechtenstein Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Liechtenstein Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Liechtenstein Lymphoma, Follicular Unavailable Reimbursed Source
Inotuzumab ozogamicin Liechtenstein Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Daratumumab Latvia Multiple Myeloma Unavailable Not reimbursed Source
Denosumab Latvia Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Latvia Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Latvia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Elotuzumab Latvia Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Latvia Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Latvia Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Latvia Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Interferon alfa-2b Latvia Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Latvia Melanoma Available Not reimbursed Source
Mogamulizumab Latvia Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Latvia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Latvia Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Not reimbursed Source
Obinutuzumab Latvia Leukemia, Lymphocytic, Chronic, B-Cell Available Not reimbursed Source
Panitumumab Latvia Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Latvia Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Not reimbursed Source
Pertuzumab Latvia Breast Neoplasms Available Not reimbursed Source
Ramucirumab Latvia Stomach Neoplasms Unavailable Not reimbursed Source
Rituximab Latvia Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Latvia Polycythemia Vera Unavailable Not reimbursed Source
Nivolumab Italy Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Italy Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Italy Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Italy Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Italy Breast Neoplasms Available Reimbursed Source
Ramucirumab Italy Stomach Neoplasms Available Reimbursed Source
Rituximab Italy Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Italy Polycythemia Vera Available Not reimbursed Source
Talimogene laherparepvec Italy Melanoma Available Not reimbursed Source
Tisagenlecleucel Italy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Italy Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Italy Breast Neoplasms Available Reimbursed Source
Atezolizumab Latvia Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Not reimbursed Source
Avelumab Latvia Carcinoma, Merkel Cell Unavailable Not reimbursed Source
Axicabtagene ciloleucel Latvia Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Latvia Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Latvia Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Brentuximab vedotin Latvia Hodgkin Disease Lymphoma, Non-Hodgkin Available Not reimbursed Source
Cemiplimab Latvia Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Latvia Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Atezolizumab Italy Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Italy Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Italy Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Bevacizumab Italy Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Italy Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Italy Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Italy Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Italy Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Italy Multiple Myeloma Available Reimbursed Source
Denosumab Italy Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Italy Neuroblastoma Available Reimbursed Source
Durvalumab Italy Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Elotuzumab Italy Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Italy Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Italy Lymphoma, Follicular Available Reimbursed Source
Inotuzumab ozogamicin Italy Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Italy Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Not reimbursed Source
Ipilimumab Italy Melanoma Available Reimbursed Source
Mogamulizumab Italy Sezary Syndrome, Mycosis Fungoides Available Not reimbursed Source
Necitumumab Italy Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Elotuzumab Ireland Multiple Myeloma Available Not reimbursed Source
Gemtuzumab ozogamicin Ireland Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Ireland Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Ireland Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Ireland Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Not reimbursed Source
Ipilimumab Ireland Melanoma Available Reimbursed Source
Mogamulizumab Ireland Sezary Syndrome, Mycosis Fungoides Available Not reimbursed Source
Necitumumab Ireland Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Nivolumab Ireland Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Ireland Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Ireland Colorectal Neoplasms Available Not reimbursed Source
Pembrolizumab Ireland Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Ireland Breast Neoplasms Available Reimbursed Source
Ramucirumab Ireland Stomach Neoplasms Available Not reimbursed Source
Rituximab Ireland Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Ireland Polycythemia Vera Available Not reimbursed Source
Talimogene laherparepvec Ireland Melanoma Available Not reimbursed Source
Tisagenlecleucel Ireland Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Ireland Breast Neoplasms Stomach Neoplasms Available Not reimbursed Source
Trastuzumab emtansine Ireland Breast Neoplasms Available Reimbursed Source
Ropeginterferon alfa-2b Iceland Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Iceland Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Iceland Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Iceland Breast Neoplasms Stomach Neoplasms Available Not reimbursed Source
Trastuzumab emtansine Iceland Breast Neoplasms Available Reimbursed Source
Atezolizumab Ireland Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Ireland Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Ireland Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Bevacizumab Ireland Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Not reimbursed Source
Blinatumomab Ireland Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Ireland Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Ireland Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Ireland Colorectal Neoplasms Head and Neck Neoplasms Available Not reimbursed Source
Daratumumab Ireland Multiple Myeloma Available Reimbursed Source
Denosumab Ireland Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Not reimbursed Source
Dinutuximab beta Ireland Neuroblastoma Available Not reimbursed Source
Durvalumab Ireland Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Pertuzumab Iceland Breast Neoplasms Available Reimbursed Source
Ramucirumab Iceland Stomach Neoplasms Unavailable Not reimbursed Source
Rituximab Iceland Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Blinatumomab Iceland Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Iceland Hodgkin Disease Lymphoma, Non-Hodgkin Unavailable Not reimbursed Source
Cemiplimab Iceland Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Iceland Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Iceland Multiple Myeloma Available Reimbursed Source
Denosumab Iceland Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Iceland Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Iceland Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Elotuzumab Iceland Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Iceland Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Iceland Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Iceland Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Interferon alfa-2b Iceland Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Iceland Melanoma Available Reimbursed Source
Mogamulizumab Iceland Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Iceland Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Iceland Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Iceland Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Iceland Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Iceland Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Interferon alfa-2b Hungary Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Reimbursed Source
Ipilimumab Hungary Melanoma Unavailable Reimbursed Source
Mogamulizumab Hungary Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Hungary Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Hungary Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Unavailable Not reimbursed Source
Obinutuzumab Hungary Leukemia, Lymphocytic, Chronic, B-Cell Unavailable Reimbursed Source
Panitumumab Hungary Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Hungary Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Unavailable Reimbursed Source
Pertuzumab Hungary Breast Neoplasms Available Reimbursed Source
Ramucirumab Hungary Stomach Neoplasms Unavailable Not reimbursed Source
Rituximab Hungary Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Hungary Polycythemia Vera Available Not reimbursed Source
Talimogene laherparepvec Hungary Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Hungary Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Hungary Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Hungary Breast Neoplasms Unavailable Reimbursed Source
Atezolizumab Iceland Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Iceland Carcinoma, Merkel Cell Unavailable Not reimbursed Source
Axicabtagene ciloleucel Iceland Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Iceland Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Talimogene laherparepvec Greece Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Greece Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Greece Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Greece Breast Neoplasms Available Reimbursed Source
Atezolizumab Hungary Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Unavailable Reimbursed Source
Avelumab Hungary Carcinoma, Merkel Cell Available Not reimbursed Source
Axicabtagene ciloleucel Hungary Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Hungary Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Hungary Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Brentuximab vedotin Hungary Hodgkin Disease Lymphoma, Non-Hodgkin Unavailable Reimbursed Source
Cemiplimab Hungary Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Hungary Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Hungary Multiple Myeloma Unavailable Reimbursed Source
Denosumab Hungary Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Hungary Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Hungary Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Elotuzumab Hungary Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Hungary Leukemia, Myeloid, Acute Unavailable Not reimbursed Source
Ibritumomab tiuxetan Hungary Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Hungary Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Daratumumab Greece Multiple Myeloma Available Reimbursed Source
Denosumab Greece Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Greece Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Greece Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Greece Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Greece Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Greece Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Greece Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Greece Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Greece Melanoma Available Reimbursed Source
Mogamulizumab Greece Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Greece Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Greece Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Greece Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Greece Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Greece Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Greece Breast Neoplasms Available Reimbursed Source
Ramucirumab Greece Stomach Neoplasms Available Reimbursed Source
Rituximab Greece Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Greece Polycythemia Vera Unavailable Not reimbursed Source
Nivolumab Germany Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Germany Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Germany Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Germany Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Germany Breast Neoplasms Available Reimbursed Source
Ramucirumab Germany Stomach Neoplasms Available Reimbursed Source
Rituximab Germany Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Germany Polycythemia Vera Available Not reimbursed Source
Talimogene laherparepvec Germany Melanoma Available Reimbursed Source
Tisagenlecleucel Germany Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Trastuzumab Germany Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Germany Breast Neoplasms Available Reimbursed Source
Atezolizumab Greece Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Greece Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Greece Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Greece Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Greece Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Greece Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Greece Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Greece Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Atezolizumab Germany Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Germany Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Germany Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Bevacizumab Germany Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Unavailable Not reimbursed Source
Blinatumomab Germany Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Germany Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Germany Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Germany Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Germany Multiple Myeloma Available Reimbursed Source
Denosumab Germany Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Germany Neuroblastoma Available Reimbursed Source
Durvalumab Germany Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Germany Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Germany Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Germany Lymphoma, Follicular Available Reimbursed Source
Inotuzumab ozogamicin Germany Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Germany Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Germany Melanoma Available Reimbursed Source
Mogamulizumab Germany Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Germany Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab France Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin France Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan France Lymphoma, Follicular Available Reimbursed Source
Inotuzumab ozogamicin France Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b France Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab France Melanoma Available Reimbursed Source
Mogamulizumab France Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab France Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab France Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab France Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab France Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab France Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab France Breast Neoplasms Available Reimbursed Source
Ramucirumab France Stomach Neoplasms Available Reimbursed Source
Rituximab France Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b France Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec France Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel France Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab France Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine France Breast Neoplasms Available Reimbursed Source
Pertuzumab Finland Breast Neoplasms Available Not reimbursed Source
Ramucirumab Finland Stomach Neoplasms Available Not reimbursed Source
Rituximab Finland Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Not reimbursed Source
Ropeginterferon alfa-2b Finland Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Finland Melanoma Available Not reimbursed Source
Tisagenlecleucel Finland Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Trastuzumab Finland Breast Neoplasms Stomach Neoplasms Available Not reimbursed Source
Trastuzumab emtansine Finland Breast Neoplasms Available Not reimbursed Source
Atezolizumab France Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab France Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel France Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Bevacizumab France Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab France Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin France Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab France Carcinoma, Squamous Cell Available Reimbursed Source
Cetuximab France Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab France Multiple Myeloma Available Reimbursed Source
Denosumab France Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta France Neuroblastoma Available Reimbursed Source
Durvalumab France Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Blinatumomab Finland Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Brentuximab vedotin Finland Hodgkin Disease Lymphoma, Non-Hodgkin Available Not reimbursed Source
Cemiplimab Finland Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Finland Colorectal Neoplasms Head and Neck Neoplasms Available Not reimbursed Source
Daratumumab Finland Multiple Myeloma Available Not reimbursed Source
Denosumab Finland Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Finland Neuroblastoma Available Not reimbursed Source
Durvalumab Finland Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Elotuzumab Finland Multiple Myeloma Available Not reimbursed Source
Gemtuzumab ozogamicin Finland Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Finland Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Finland Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Interferon alfa-2b Finland Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Finland Melanoma Available Not reimbursed Source
Mogamulizumab Finland Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Finland Carcinoma, Non-Small-Cell Lung Available Not reimbursed Source
Nivolumab Finland Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Not reimbursed Source
Obinutuzumab Finland Leukemia, Lymphocytic, Chronic, B-Cell Available Not reimbursed Source
Panitumumab Finland Colorectal Neoplasms Available Not reimbursed Source
Pembrolizumab Finland Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Not reimbursed Source
Interferon alfa-2b Estonia Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Estonia Melanoma Available Not reimbursed Source
Mogamulizumab Estonia Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Estonia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Estonia Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Estonia Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Estonia Colorectal Neoplasms Available Not reimbursed Source
Pembrolizumab Estonia Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Estonia Breast Neoplasms Available Reimbursed Source
Ramucirumab Estonia Stomach Neoplasms Available Not reimbursed Source
Rituximab Estonia Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Estonia Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Estonia Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Estonia Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Estonia Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Estonia Breast Neoplasms Available Reimbursed Source
Atezolizumab Finland Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Not reimbursed Source
Avelumab Finland Carcinoma, Merkel Cell Available Not reimbursed Source
Axicabtagene ciloleucel Finland Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Finland Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Not reimbursed Source
Talimogene laherparepvec Denmark Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Denmark Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Trastuzumab Denmark Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Denmark Breast Neoplasms Available Reimbursed Source
Atezolizumab Estonia Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Estonia Carcinoma, Merkel Cell Unavailable Not reimbursed Source
Axicabtagene ciloleucel Estonia Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Estonia Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Estonia Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Estonia Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Estonia Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Estonia Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Estonia Multiple Myeloma Available Reimbursed Source
Denosumab Estonia Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Estonia Neuroblastoma Available Not reimbursed Source
Durvalumab Estonia Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Estonia Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Estonia Leukemia, Myeloid, Acute Available Not reimbursed Source
Ibritumomab tiuxetan Estonia Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Estonia Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Daratumumab Denmark Multiple Myeloma Available Reimbursed Source
Denosumab Denmark Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Denmark Neuroblastoma Available Reimbursed Source
Durvalumab Denmark Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Denmark Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Denmark Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Denmark Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Denmark Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Denmark Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Denmark Melanoma Available Reimbursed Source
Mogamulizumab Denmark Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Denmark Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Denmark Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Denmark Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Denmark Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Denmark Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Denmark Breast Neoplasms Available Reimbursed Source
Ramucirumab Denmark Stomach Neoplasms Available Reimbursed Source
Rituximab Denmark Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Denmark Polycythemia Vera Available Reimbursed Source
Ropeginterferon alfa-2b Czechia Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Czechia Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Czechia Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Czechia Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Czechia Breast Neoplasms Available Reimbursed Source
Atezolizumab Denmark Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Denmark Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Denmark Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Bevacizumab Denmark Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Denmark Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Denmark Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Denmark Carcinoma, Squamous Cell Available Reimbursed Source
Cetuximab Denmark Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Nivolumab Czechia Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Czechia Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Czechia Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Czechia Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Czechia Breast Neoplasms Available Reimbursed Source
Ramucirumab Czechia Stomach Neoplasms Available Reimbursed Source
Rituximab Czechia Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Atezolizumab Czechia Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Not reimbursed Source
Avelumab Czechia Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Czechia Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Available Not reimbursed Source
Bevacizumab Czechia Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Czechia Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Czechia Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Czechia Carcinoma, Squamous Cell Available Not reimbursed Source
Cetuximab Czechia Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Czechia Multiple Myeloma Available Reimbursed Source
Denosumab Czechia Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Czechia Neuroblastoma Available Not reimbursed Source
Durvalumab Czechia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Elotuzumab Czechia Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Czechia Leukemia, Myeloid, Acute Unavailable Not reimbursed Source
Ibritumomab tiuxetan Czechia Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Czechia Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Reimbursed Source
Interferon alfa-2b Czechia Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Czechia Melanoma Available Reimbursed Source
Mogamulizumab Czechia Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Czechia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Elotuzumab Cyprus Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Cyprus Leukemia, Myeloid, Acute Unavailable Not reimbursed Source
Ibritumomab tiuxetan Cyprus Lymphoma, Follicular Available Not reimbursed Source
Inotuzumab ozogamicin Cyprus Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Interferon alfa-2b Cyprus Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Cyprus Melanoma Available Not reimbursed Source
Mogamulizumab Cyprus Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Cyprus Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Cyprus Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Cyprus Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Cyprus Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Cyprus Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Cyprus Breast Neoplasms Available Reimbursed Source
Ramucirumab Cyprus Stomach Neoplasms Available Not reimbursed Source
Rituximab Cyprus Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Cyprus Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Cyprus Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Cyprus Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Cyprus Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Cyprus Breast Neoplasms Available Reimbursed Source
Pertuzumab Croatia Breast Neoplasms Available Reimbursed Source
Ramucirumab Croatia Stomach Neoplasms Available Reimbursed Source
Rituximab Croatia Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Croatia Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Croatia Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Croatia Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Trastuzumab Croatia Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Croatia Breast Neoplasms Available Reimbursed Source
Atezolizumab Cyprus Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Cyprus Carcinoma, Merkel Cell Unavailable Not reimbursed Source
Axicabtagene ciloleucel Cyprus Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Cyprus Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Cyprus Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Not reimbursed Source
Brentuximab vedotin Cyprus Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Cyprus Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Cyprus Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Cyprus Multiple Myeloma Available Reimbursed Source
Denosumab Cyprus Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Cyprus Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Cyprus Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Blinatumomab Croatia Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Brentuximab vedotin Croatia Hodgkin Disease Lymphoma, Non-Hodgkin Available reimbursed Source
Cemiplimab Croatia Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Croatia Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Croatia Multiple Myeloma Available Reimbursed Source
Denosumab Croatia Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Croatia Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Croatia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Elotuzumab Croatia Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Croatia Leukemia, Myeloid, Acute Unavailable Not reimbursed Source
Ibritumomab tiuxetan Croatia Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Croatia Precursor Cell Lymphoblastic Leukemia-Lymphoma Unavailable Not reimbursed Source
Interferon alfa-2b Croatia Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Croatia Melanoma Unavailable Not reimbursed Source
Mogamulizumab Croatia Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Croatia Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Croatia Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Croatia Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Croatia Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Croatia Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Interferon alfa-2b Bulgaria Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Unavailable Not reimbursed Source
Ipilimumab Bulgaria Melanoma Available Reimbursed Source
Mogamulizumab Bulgaria Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Bulgaria Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Bulgaria Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Bulgaria Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Bulgaria Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Bulgaria Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Bulgaria Breast Neoplasms Available Reimbursed Source
Ramucirumab Bulgaria Stomach Neoplasms Available Reimbursed Source
Rituximab Bulgaria Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Bulgaria Polycythemia Vera Unavailable Not reimbursed Source
Talimogene laherparepvec Bulgaria Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Bulgaria Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Bulgaria Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Bulgaria Breast Neoplasms Available Reimbursed Source
Atezolizumab Croatia Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Croatia Carcinoma, Merkel Cell Unavailable Not reimbursed Source
Axicabtagene ciloleucel Croatia Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Croatia Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Talimogene laherparepvec Belgium Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Belgium Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Available Reimbursed Source
Trastuzumab Belgium Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Belgium Breast Neoplasms Available Reimbursed Source
Atezolizumab Bulgaria Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Bulgaria Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Bulgaria Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Bulgaria Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Bulgaria Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Bulgaria Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Bulgaria Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Bulgaria Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Bulgaria Multiple Myeloma Available Reimbursed Source
Denosumab Bulgaria Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Bulgaria Neuroblastoma Unavailable Not reimbursed Source
Durvalumab Bulgaria Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Bulgaria Multiple Myeloma Unavailable Not reimbursed Source
Gemtuzumab ozogamicin Bulgaria Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Bulgaria Lymphoma, Follicular Unavailable Not reimbursed Source
Inotuzumab ozogamicin Bulgaria Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Daratumumab Belgium Multiple Myeloma Available Reimbursed Source
Denosumab Belgium Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Belgium Neuroblastoma Available Not reimbursed Source
Durvalumab Belgium Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Belgium Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Belgium Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Belgium Lymphoma, Follicular Available Reimbursed Source
Inotuzumab ozogamicin Belgium Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Belgium Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Belgium Melanoma Available Reimbursed Source
Mogamulizumab Belgium Sezary Syndrome, Mycosis Fungoides Unavailable Not reimbursed Source
Necitumumab Belgium Carcinoma, Non-Small-Cell Lung Unavailable Not reimbursed Source
Nivolumab Belgium Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Belgium Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Belgium Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Belgium Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Belgium Breast Neoplasms Available Reimbursed Source
Ramucirumab Belgium Stomach Neoplasms Available Reimbursed Source
Rituximab Belgium Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Belgium Polycythemia Vera Unavailable Not reimbursed Source
Nivolumab Austria Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available Reimbursed Source
Obinutuzumab Austria Leukemia, Lymphocytic, Chronic, B-Cell Available Reimbursed Source
Panitumumab Austria Colorectal Neoplasms Available Reimbursed Source
Pembrolizumab Austria Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available Reimbursed Source
Pertuzumab Austria Breast Neoplasms Available Reimbursed Source
Ramucirumab Austria Stomach Neoplasms Available Reimbursed Source
Rituximab Austria Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available Reimbursed Source
Ropeginterferon alfa-2b Austria Polycythemia Vera Available Reimbursed Source
Talimogene laherparepvec Austria Melanoma Unavailable Not reimbursed Source
Tisagenlecleucel Austria Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Trastuzumab Austria Breast Neoplasms Stomach Neoplasms Available Reimbursed Source
Trastuzumab emtansine Austria Breast Neoplasms Available Reimbursed Source
Atezolizumab Belgium Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available Reimbursed Source
Avelumab Belgium Carcinoma, Merkel Cell Available Reimbursed Source
Axicabtagene ciloleucel Belgium Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Unavailable Not reimbursed Source
Bevacizumab Belgium Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available Reimbursed Source
Blinatumomab Belgium Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Brentuximab vedotin Belgium Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Belgium Carcinoma, Squamous Cell Unavailable Not reimbursed Source
Cetuximab Belgium Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Brentuximab vedotin Austria Hodgkin Disease Lymphoma, Non-Hodgkin Available Reimbursed Source
Cemiplimab Austria Carcinoma, Squamous Cell Available Reimbursed Source
Cetuximab Austria Colorectal Neoplasms Head and Neck Neoplasms Available Reimbursed Source
Daratumumab Austria Multiple Myeloma Available Reimbursed Source
Denosumab Austria Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available Reimbursed Source
Dinutuximab beta Austria Neuroblastoma Available Reimbursed Source
Durvalumab Austria Carcinoma, Non-Small-Cell Lung Available Reimbursed Source
Elotuzumab Austria Multiple Myeloma Available Reimbursed Source
Gemtuzumab ozogamicin Austria Leukemia, Myeloid, Acute Available Reimbursed Source
Ibritumomab tiuxetan Austria Lymphoma, Follicular Available Reimbursed Source
Inotuzumab ozogamicin Austria Precursor Cell Lymphoblastic Leukemia-Lymphoma Available Reimbursed Source
Interferon alfa-2b Austria Carcinoid Tumor, Leukemia, Hairy Cell, Lymphoma, Follicular, Hepatitis B, Chronic, Hepatitis C, Chronic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Melanoma, Multiple Myeloma Available Reimbursed Source
Ipilimumab Austria Melanoma Available Reimbursed Source
Mogamulizumab Austria Sezary Syndrome, Mycosis Fungoides Available Reimbursed Source
Necitumumab Austria Carcinoma, Non-Small-Cell Lung Available Reimbursed Source

Links

Downloads